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Stent Placement for Chronic Iliac Arterial
Occlusive Disease: the Results of 10 Years
Experience in a Single Institution
Objective: We wanted to retrospectively evaluate the long-term therapeutic results
of iliac arterial stent placement that was done in a single institution for 10 years.
Materials and Methods: From May 1994 to April 2004, 206 patients who
underwent iliac arterial stent placement (mean age; 64 8.8) were followed up for
evaluating the long term stent patency. Combined or subsequent bypass surgery
was performed in 72 patients. The follow up period ranged from one month to 120
months (mean; 31 25.2 months). The factors that were analyzed for their effect
on the patency of stents were age, the stent type and diameter, the lesion site,
lesion shape, lesion length, the Society of Cardiovascular and Interventinal
Radiology criteria, the total run off scores, the Fontaine stage and the cardiovas-
cular risk factors (diabetes mellitus, hypertension and smoking). Follow-up includ-
ed angiography and/or CT angiography, color Doppler sonography and clinical
evaluation with the ankle-brachial index. 
Results: Two hundred and eighty-four stents were placed in 249 limbs of 203
patients. The technical success rate was 98% (203/206). The primary patency
rates of the stents at 3, 5, 7 and 10 year were 87%, 83%, 61% and 49%, respec-
tively. One hundred seventy-seven patients maintained the primary stent patency
until the final follow up and 26 patients showed stenosis or obstruction during the
follow up. Secondary intervention was performed in thirteen patients. Lesions in
the external iliac artery (EIA) or lesions in both the common iliac artery (CIA) and
EIA were a poor prognostic factor for stent patency. The run off score and stent
diameter also showed statistically significant influence on stent patency. The
overall complication rate was 6%.
Conclusion: Iliac arterial stent placement is a safe treatment with favorable
long term patency. Lesions in the EIA or lesions in both the EIA and CIA, poor run
off vessels and a stent having the same or a larger diameter than 10 mm were
the poor prognostic factors for long term stent patency.
ince the first successful aortoiliac angioplasty was done in 1980 (1 3),
and with the appearance of vascular stents in the late 1980s, angioplasty
and/or stent placement has provided new therapeutic options for the
treatment of chronic aortoiliac occlusive disease.
However, according to several reports, performing only percutaneous transluminal
angioplasty (PTA) for irregular, eccentric, long, ulcerated stenoses and occlusions has
demonstrated unsatisfactory long-term patency rates (4 7). 
Endovascular stenting for iliac arterial occlusive disease has recently shown some
good results and this technique has become widely accepted as a primary treatment
for iliac arterial occlusive disease (8 11). The long-term clinical results of iliac arterial
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Sstenting are important baseline factors for determining the
therapeutic options and there have been several reports
concerning the 5-year follow up results of iliac arterial
stent placement. However, in spite of the various clinical
studies, the 10-year survey data is still somewhat limited
(12) and any report concerning 10 years experience at a
single Asian institution is rare. 
The purpose of our study was to evaluate the long-term
therapeutic results of iliac arterial stent placement by
conducting a retrospective review of a 10-year period in a
single institution. 
MATERIALS AND METHODS
Patient population and stent placement
A total of 206 patients who underwent iliac arterial stent
placement from May, 1994 to April, 2004 were retrospec-
tively evaluated for their long-term stent patency. One
hundred ninty-eight patients were male and eight were
female (the ages ranged from 48 to 84 years, mean age: 64
years). 
No absolute exclusion criteria were used other than a
patient’s refusal to participate in our study. The patients
who were proven to have iliac arterial occlusive disease on
Doppler ultrasonography, CT angiography or by the low
ankle brachial index (ABI) were the candidates for stent
insertion and most of these patients wanted to avoid the
surgical risk and comorbidities.
We performed primary stenting as a baseline treatment
strategy unless there was an absolute demand for only
angioplasty from the patients and/or the clinical depart-
ment. The policy of primary stenting was based on the
reports by Vorwerk and Nawaz (13, 14). However, the
finding of more than 30% residual stenosis after repeated
angioplasty or a flow limiting dissection was also used as
additional criteria for stenting.
Informed consents were obtained from all the patients or
from their legally responsible guardian. 195 patients (95%)
underwent stent placement in an angiographic clinic under
local anesthesia and 11 patients underwent intraoperative
stent placement. The procedure for primary stenting
included the placement of a 7 F introducer sheath ipsilater-
ally, and then a 0.035-inch guide wire (Glidewire, Terumo,
Tokyo, Japan), was passed through the stenotic segment.
The stent was subsequently placed over the guide wire to
completely cover the stenotic segment. If this failed, an
antegrade approach to stenting was attempted with using
the contralateral common femoral artery (CFA).
Fluoroscopic “road maps” were used to precisely place the
stent. The diameters of the stents we used were measured
from the normal proximal or distal segments on either side
of the stenoses and also from the contralateral correspond-
ing artery. After deployment, the self-expandable stents
were routinely dilated with using a balloon catheter that
had a diameter from 6 mm to 10 mm. Poststent
angiographic images were obtained with the bilateral
oblique view and the anterior-to-posterior view. All the
patients were given an intravenous bolus of 80 IU/kg
heparin during their procedures. During the initial period
of study, the administered medications after the procedure
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Table 1. The Number of Patients Who Underwent Combined Bypass Surgery
Types of Bypass Graft Graft Graft Total
Surgery Before Stent Before and After Stent After Stent
Femoro-femoral 1 27 28
Femoro-popliteal 3 1 20 24
Ilio-popliteal 02 02
Aorto-iliac 1 01
Aorto-femoral 02 02
Femoro-tibial 01 01
Popliteal-tibial 1 01
Femoro-femoral and 09 09 
femoro-popliteal
Femoro-popliteal and 01 01
ilio-popliteal
Aorto-femoral and 02 02
femoro-popliteal
Femoro-femoral and 01 01
-popliteal and
Graft-popliteal
Total 6 1 65 72included asprin (500 mg per day) and dipyridamole (225
mg per day for 3 6 months). During the midterm study
period, aspirin (325 mg per day) and ticlopidine (100 mg
1T b.i.d. for 3 6 months) was used for the post-stent
medication. After Feb. 2000, the post-stent medication was
changed to aspirin (100 mg per day) and clopidogrel (75
mg per day for 3 6 months). 
The decision of which stent to use was left to the discre-
tion of the operator, but balloon-expandable stents were
usually deployed for the focal or short segmental lesions,
and self-expandable stents were deployed for the long
segmental or diffuse lesions. Various types of stent were
used. The original Palmaz, Palmaz Corinthian, Palmaz
GENESIS stent (Cordis Europa N.V., Johnson & Johnson’s
Corp, The Netherlands), and the EXPRESS LD stent
(Boston Scientific, MA, USA) were the balloon expandable
stents that were used. The self-expandable stents included
the Wallstent (Schneider, Boston scientific, MA, USA), the
Niti-S stent (Taewoong Medical, Seoul, Korea), the
SMART stent (Johnson & Johnson’s Cordis Corp, Miami
Lakes, FL), and the Symphony stent (Boston Scientific
vascular, Natick, MA). 
Combined bypass graft surgery was performed in 72 of
203 (35%) patients (Table 1) (Fig. 1). Six patients
underwent bypass surgery before their stenting and the
stent was inserted for the additional newly developed iliac
lesions. Sixty-five patients underwent bypass surgery after
their stent insertion. When the stent was placed prior to
bypass surgery, the subsequent bypass surgery was
performed within one hospital stay. One patient had an
occluded femoropopliteal bypass graft before their stent
insertion. Therefore, this patient underwent another
femoropopliteal bypass after placement of the stent. For
the patients with coexisting contralateral long segmental
obstruction of the common and external iliac arteries, we
performed ipsilateral stent placement and subsequent
crossfemoral bypass surgery. For the patients with bilateral
diffuse iliac arterial disease or for the patients with poor
distal run off vessels, a combination of bypass surgery such
as aortofemoral or femoropopliteral bypass surgery was
performed before or after stent placement. 
Data Analysis and Study Endpoints
The sites of the lesions were recorded from the common
iliac artery (CIA) to the external iliac artery (EIA). The
patients having lesions at both the CIA and EIA were also
described. The shapes and distribution of the lesions were
recorded under the categorization of focal stenosis,
segmental stenosis, multifocal or diffuse stenosis, and
complete obstruction. Focal stenosis was defined as a
localized, flow limiting stenosis that was less than 1 cm in
total length. Those lesions having a measurable distance or
if there were more than two continuous lesions that
consisted of narrowed segments, then they were consid-
ered as segmental lesions. Multifocal or diffuse stenosis was
indicated by the presence of more than two separated flow
limiting stenotic lesions in a tandem location or by the
presence of bilateral diffuse disease.
The lesion lengths were recorded in each lesion from the
baseline angiographic images and they were classified into
four categories; lesions less than 3 cm, 3 5 cm, 6 9 cm
and then lesions equal to or greater than 10 cm in length.
For the patients having multifocal or diffuse stenosis, the
distance from the most proximal stenosis to the most distal
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Fig. 1. A. A 64-year-old male patient
shows complete obstruction of both the
common iliac artery and the external
iliac artery. This patient underwent stent
placement at the right common iliac
artery and the external iliac artery with
subsequent femorofemoral bypass graft
surgery. 
B. The 48 month follow up arteriography
shows the well preserved patency of the
stent at the right common iliac artery
and the external iliac artery (arrow) and
the femorofemoral bypass graft
(arrowheads). 
ABstenosis was considered as the total length of the lesion.
The lesion’s lengths were categorized according to the
criteria of the Society of Cardiovascular and Interventional
Radiology (SCVIR) (Table 2), and all the patients were
grouped into the four classes of the SCVIR classification
(11). 
The status of the femoral runoff vessels was scored for
each limb according to the Society of Vascular
Surgery/International Society of Cardiovascular Surgery
(SVS/ISCVS) grading system (Table 3) (15). For the
patients who did not undergo bypass surgery, the pre-stent
angiographic images were used for grading the run off
scores. However, a coexisting patent ipsilateral femoro-
popliteal bypass graft was considered as a patent superfi-
cial femoral artery (SFA). In addition, the patient who
underwent prestenting and/or poststenting bypass surgery
was also considered as having patent distal run off vessels.
If contralateral iliac stenting was performed along with
femorofemoral bypass surgery, then the run-off score was
based on the ipsilateral lesion site limb.
Immediate poststent technical success was defined when
there was less than 30% residual stenosis, restoration of a
rapid antegrade flow was noted angiographically, and/or
there was less than a 10 mmHg resting transstenotic mean
pressure gradient on the homodynamic ‘pull-back’
measurement with using a single transducer. 
For a vessel to be considered patent during follow-up, a
treated limb had to meet the study’s clinical criteria (no
intervening percutaneous or surgical intervention involving
the iliac artery, and no deterioration in the clinical status),
the noninvasive criteria (an ABI maintained within 15% of
the maximum post-stenting value or there was no evidence
of restenosis on the color Doppler US), and when it was
performed, the angiographic criteria (no evidence of
restenosis). Restenosis was defined as more than a 30%
reduction of diameter inside or at the ends of the stents, as
noted on the CT angiography or on the digital subtraction
angiography, and/or a greater than 2.5 peak systolic
velocity ratio on the color duplex ultrasonography. Limbs
that violated any of these criteria were considered to be
occluded for the purposes of the analysis. 
The symptoms and clinical severity of the lower extrem-
ity ischemia were classified and followed by using the
Fontaine classification (Table 4) (8). The definition of the
patency was consistent with the reporting guidelines
suggested by Sacks (15).
Follow up of stent patency was performed with using
both the medical imaging and the clinical assessment. The
imaging modalities included conventional angiography, CT
angiography and/or color Doppler ultrasonography. The
clinical assessment consisted of the ABI, symptomatic
evaluation and the physical examination. The follow up
intervals were somewhat irregular before Feb. 1999, but
since then, the immediate postprocedural measurement of
the ABI was followed up at 3 month, 6 month, 12 month
and at each following year. Conventional angiography was
indicated when the color Doppler sonography and/or ABI
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Table 3. Weighting of the Runoff Vessels
Site of No. of Units Assigned
Intervention 3 2 1
CIA EIA IIA
EIA CFA SFA PFA
CFA SFA PFA
SFA, POP AT, PT, PER
AT Distal tibial Pedal arch
PT  Distal tibial Pedal arch
PER Pedal arch Collaterals to 
AT and PT
DP Pedal arch
Note. CIA = common iliac artery, EIA = external iliac artery, IIA =
internal iliac artery, CFA = common femoral artery, SFA = superficial
femoral artery, POP = popliteal artery, PFA = profunda femoral artery,
AT= anterior tibial artery, PT = posterior tibial artery, PER = peroneal
artery, DP = dorsalis pedis artery
*Points assigned for degree of occlusion: 3 = occluded throughout most of
its length; 2.5 = occluded for less than half its length with visible
collaterals; 2 = 50%-99% stenosed;1 = 20 49% stenosed; 0 = normal or
minimal evidence of disease (ie, less than 20% narrowing)
Table 4. Fontaine Classification
Stage Definition
I Asymptomatic
IIa Intermittent claudication > 200 m 
IIb Intermittent claudication < 200 m
III Rest pain
IV Necrosis/Gangrene
Table 2. The SCVIR Lesion Classification
Category No.    Definition
1             Stenoses < 3 cm long that are concentric and 
noncalcified
2             Stenoses 3 5 cm long, or eccentric or
calcified stenoses < 3 cm long
3             Stenoses 5 10 cm long or chronic occlusions
< 5 cm long
4             Stenoses greater than 10 cm long, chronic
occlusions greater than 5 cm long, extensive
bilateral aortoiliac atherosclerotic disease,
stenosis in patients with abdominal aortic
aneurysm or other lesions requiring aortic or
iliac surgerysuggested the presence of in-stent restenosis or obstruction.
A decrease of more than 15% of the post-stent maximum
ABI was regarded as stent failure. CT angiography was
mainly recommended for those patients who maintained
uninterrupted patency for more than 12 months of follow
up. CT angiography was performed at a six month or one
year interval at the outpatient clinic, according to the
decision of the physician.
The follow up data was collected by reviewing the
medical records and by interpreting the follow up medical
images. When the imaging follow-up result was not
available, the results of a physical and the symptomatic
evaluation done at the outpatient department were used
for determining patency. For the cases that were lacking
the outpatient clinical examination data, telephone
interviews were performed for evaluating the clinical
symptoms, the life quality and the interval changes or the
degree of the present claudication as compared with the
immediate post-stent period. 
The cardiovascular risk factors were recorded; these
were based on the medical records and they included
diabetes, smoking and hypertension. 
Statistical Analysis
The basic unit of analysis was the limb and not the
patient. The time of the primary patency of the stent was
calculated by performing a survival analysis with the
Kaplan-Meier method.
Because only six of the 206 patients (0.03%) were
female in this study, gender was excluded from the statisti-
cal analysis. Age, stent type and diameter, the lesion site,
lesion shape, lesion length, the SCVIR classification, the
total run off scores, the Fontaine classification and the
cardiovascular risk factors (diabetes mellitus: DM,
hypertonsim: HT and smoking) were analyzed with the
Breslow test to screen for variables that affected the
primary patency of the stent. 
All the factors included in the Breslow test were
evaluated for their relationship with stent patency by using
the Cox proportional hazards test to compensate and
adjust for the effect of each predictor variable.
The pre-stent ABI and the post-stent ABI, the
transstenotic pressure gradients and the changes of the
Fontaine classification were compared by using paired t
tests.
RESULTS
Two hundred eighty-four stents were placed in 249 limbs
of 203 patients. In four limbs of three patients, the
procedure failed due to the failure of the guide wire to pass
across the lesion. The immediate technical success rate was
98% (203/206). Single limb treatment was performed in
157 patients (77%) and bilateral stent placement was
performed in 46 patients (23%). Eleven patients
underwent intraoperative stent placement.
The number of balloon expandable stents placed was 54
Palmaz stents and three EXPRESS LD stents. The number
of self-expandable stent placed was as follows; Wallstent (n
= 106), Niti-S stent (n = 5), SMART stent (n = 114), and
the Symphony stent (n = 2). The stent diameter ranged
from 6 mm to 14 mm, and the number of stents used was:
6 mm (n = 4), 7 mm (n = 19), 8 mm (n = 139), 9 mm (n =
42), 10 mm (n = 74), 12 mm (n = 5), and 14 mm (n = 1). 
Lesions were identified in the CIA (n = 95), the EIA (n =
106), and both the common and external iliac arteries (n =
48). The shapes of the lesion were 106 focal stenoses, 82
segmental stenoses, 21 multifocal or diffuse stenoses, and
40 limbs with complete obstruction. The number of lesions
in each category of the lesions’ length was: below 3 cm (n
= 125), 3 5 cm (n = 62), 6 9 cm (n = 44), and more than
10 cm (n = 18).
According to the classification of the SCVIR, 51 lesions
(20%) were category 1, 86 (35%) lesions were category 2,
72 lesions (29%) were category 3, and 40 lesions (16%)
were category 4.
Eighty limbs (32%) showed a flow limiting stenosis or
obstruction at the SFA, and eight limbs had lesions in the
CFA. Compromise of the profunda femoral artery (PFA)
was seen in 10 limbs. The mean value of the total run off
score was 0.9 1.8.
The pre- and post-stent ABI records were available in 74
limbs of 62 patients and the mean ABI value was increased
from 0.7 0.2 before stent placement to 0.9 0.1 after
stent placement. For the other patients who lacked a pre-
stent ABI value, follow up of the ABI was also performed.
Improvement of the ABI after stent placement showed
statistically significant changes on a paired t test (p = 0.02)
The mean transstenotic pressure gradients were available
for 84 patients. The mean pressure gradient decreased
from 21.3 15.6 mmHg to 1.3 5.4 mmHg before and
after stent placement, respectively. The pressure gradients
also showed statistically significant improvement on paired
t tests (p = 0.00). 
One hundred eighty-seven patients had a pre- and post-
stent Fontaine classification. The median value of the
Fontaine classification changed from 3 to 2 before and
after stent placement, respectively. The changes of the
Fontaine classification before and after treatment are
shown in Table 5 and there was statistically significant
improvement of the Fontaine stage on paired t tests (p =
0.00). 
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causes of death were gastrointestinal bleeding for one
patient, myocardial infarction in three patients, diabetic
nephropathy in two patients, sepsis associated with chronic
renal failure in two patients and hepatocellular carcinoma
in one patient. 
The lengths of the follow up periods ranged from one
month to 120 months (mean: 31 25.2 months). Doppler
ultrasonography was performed in all the patients during
the follow up periods according to the follow up protocol.
Thirty-one conventional angiographies were performed in
30 patients, and CT angiography was performed in 49
patients. Determination of the final stent patency was
based on Doppler sonography in 70 patients, ABI in 36
patients, CT angiography in 29 patients, conventional
angiography in 19 patients and by a clinical decision with a
phone call and/or a physical examination for 49 patients.
Overall, complications occurred in 12 of the 203 patients
(6%). Major complications that required further manage-
ment were seen in six of the 203 patients (3%). One
patient who underwent common iliac artery stent
placement showed acute thrombotic occlusion of the
common femoral artery within 24 hours after the stent
placement. The occluded common femoral artery was
treated with thrombolysis. The balloon or stent associated
dissections were treated by the additional placement of
stents in three patients. Overlay of the stent upper margin
on the contralateral common iliac orifice occurred in two
patients, and so additional stent placement was performed
in the contralateral common iliac artery.
Minor complications that were treated with conservative
management and/or medical management were seen in six
of the 203 patients (3%). Four patients with distal embolic
occlusion of the infrapopliteal small branch vessel
improved on the clinical follow-up with instituting antico-
agulation therapy only. Hemodynamically insignificant
small antegrade dissections associated with the stent were
seen in three patients, and these were left alone without
further management.
One hundred seventy-seven of the 203 patients (87%)
maintained uninterrupted stent patency until the final
follow-up (Fig. 2). 26 of the 203 (13%) patients presented
with stenosis or obstruction of their stents on the follow up
imaging studies. Secondary intervention was performed in
a total of thirteen patients. Eleven patients were continu-
ously followed up thereafter, but the follow up data was
not available for two patients after they underwent
secondary intervention. Restenosed stents were left
without further intervention in nine patients. Subsequent
bypass surgery was performed in four patients who were
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Fig. 2. A 68-year-old male patient
underwent left common iliac artery and
external iliac artery stent placement on
October 1994. The patient had a
completely occluded right
femoropopliteal bypass graft. 
A. The angiograms obtained 5-years
after stent placement show the well
preserved stent patency without any
hemodynamically significant stenosis. 
B. Follow-up angiography performed on
March 2003 (101 months from the initial
stent placement) also shows the good
instent flow without significant stenosis.
Note the minimal progression of the
eccentric stenosis (arrow) at the
proximal portion of the stent, but this is
hemodynamically insignificant. Newly
developed occlusion of right external
iliac artery can be seen (curved arrow).    AB
Table 5. Change of the Fontaine Stage Before and After
Stent Placement
Fontaine Stage Before Stent After Stent
Stage No.
I 007 082
IIa 063 059
IIb 096 036
III 008 003
IV 013 007
Total 187 187
Change of Fontaine stage
3 009
2 042
1 068
0 059
1 006
2 003identified as having stent obstruction. 
The cardiovascular risk factors were diabetes in 74
patients (36%), hypertension in 126 patients (62%), and
smoking in 151 patients (74%). 
Statistical analysis and the predictors of outcome
The cumulative primary patency rates with their
confidence intervals (CI) and standard errors (SE) for the
iliac arterial stent placement at 3, 5, 7 and 10 years were
87% (95% CI: 0.81 0.92, SE: 0.03), 83% (95% CI:
0.76 0.90, SE: 0.04), 61% (95% CI: 0.39 0.84, SE:
0.11), and 49% (95% CI: 0.21 0.77, SE: 0.14), respec-
tively (Fig. 3). 
Age, the stent type and diameter, lesion site, lesion
shape, SCVIR classification, the total run off scores, the
Fontaine classification and the cardiovascular risk factors
(DM, HT, smoking) were analyzed with using Breslow
tests to screen for variables that affected the primary
patency of the stent, but none of these variables showed a
statistically significant relationship with the primary stent
patency. Except for the stent type and the lesion length
that were excluded from the Cox regression analysis
because one of the frequencies of these subcategory was
too small for analysis, all the other variables in the Breslow
test were included in the multivariate Cox regression
model. 
According to the occlusion hazard rate analysis with
using Cox regression testing, with the assumption that the
other variables are constant, the lesion site (p = 0.025), the
Park et al.
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Fig. 3. The cumulative primary stent patency calculated by
Kaplan-Meier analysis.
Table 6. The Results of the Cox Proportional Hazards Multivariate Model
95% CI for Exp
Variables Hazard ratio S.E. p
Lower      Upper
Age .0926 .505 .087 9.344 2.492             
DM 1.935 .491 .179 .739 5.062
Hypertension 1.178 .467 .726 .471 2.945
Smoking 1.649 .547 .360 .565 4.818
Lesion site .025
Lesion site (EIA) .243 .576 .028 .078 .750
Lesion site (CIA & EIA) .088 1.078 .048 .011 .724
Lesion shape .522
Segmental lesion 1.493 .575 1.000 .483 4.610 
Multifocal or diffuse lesion 1.710 .949 1.000 .266 10.989 
Obstruction .508 .798 1.000 .106 2.425 
SCVIR .265
SCVIR 2 .799 .670 1.000 .215 2.970
SCVIR 3 2.774 .736 .498 .655 11.749  
SCVIR 4 1.959 .961 1.000 .298 12.877
Stent diameter .032
Stent diameter ( 9 mm) .382 .702 .342 .097 1.512
Stent diameter ( > 9 mm) .091 .922 .018 .015 .554 
Fontaine .991
Fontaine IIa .724 1.131 1.000 .079 6.643  
Fontaine IIb .714 1.154 1.000 .074 6.860
Fontaine III .504 1.492 1.000 .027 9.389
Fontaine IV .543 1.550 1.000 .026 11.316
Total Run off scores 1.194 .097 .048 1.007 1.472
Note. SE = standard error, p = Significance, 95% CI = 95% confidence interval of the relative risk, SCVIR = Society of Cardiovascular and Interventional
Radiology, DM = diabetes mellitus, EIA = external iliac artery, CIA = common iliac artery stent diameter (p = 0.032), and the run off score (p =
0.048) showed to have a statistically significant influence
on the primary stent patency (Table 6). When the iliac
lesions were located at the EIA, the occlusion hazard rate
was 24% higher than in the cases having CIA lesion only
(p = 0.03). For the patients having lesions at both the CIA
and EIA, the occlusion hazard rate was 9% times higher
than for the cases with CIA lesion (p = 0.048). Stents
having the same or larger diameter than 10 mm showed
9% higher occlusion hazard rate than a stent with a
diameter less than 10 mm (p = 0.02). However, the group
having a stent with a diameter less than 8 mm or the group
having a stent 8 mm or 9 mm in diameter showed no statis-
tically significant difference between the occlusion hazard
rate (p = 0.02). With increasing the run off scores by one
point, the occlusion hazard rate was increased 1.194 times
(p = 0.048). The lesion shape, SCVIR classification, cardio-
vascular risk factors (DM, HT, smoking) and Fontaine
classification showed no statistically significant influence
on stent patency. 
Comparison of the ABI (p = 0.02), the Fontaine classifi-
cation (p = 0.00), and the transstenotic pressure gradients
(p = 0.00) before and after stent placement showed statisti-
cally significant improvement on the paired t test. 
DISCUSSION
In spite of the good long-term patency that’s been
observed for surgical bypass grafting, the surgical manage-
ment of aortoiliac insufficiency in the patients with
intermittent claudication has been discouraged because of
the risks associated with the aortoiliac bypass surgery.
According to the surgical experiences of six large series
that involved 1,270 patients who were treated for claudi-
cation and limb-threatening ischemia, the weighted surgical
mortality was 4%, and major complications were seen in
21% of the cases (16 20). The complications of aortoiliac
bypass surgery are significant and they include myocardial
infarction, congestive heart failure, multisystem organ
failure, stroke, spinal cord ischemia, intestinal infarction,
aortoenteric fistula, acute renal failure and respiratory
failure. 
Balloon angioplasty represents a less invasive therapeutic
option for the treatment of patients with aortoiliac insuffi-
ciency, and it has been demonstrated to have acceptable
associated risk for the patients suffering with intermittent
claudication. As a consequence, balloon angioplasty
remains the gold standard for the percutaneous treatment
of aortoiliac stenosis (21). Becker et al. analyzed 2,697
procedures and they found an average technical success
rate of 92%, a 2-year patency rate of 81% and a 5-year
patency rate of 72% (7). Although these results are quite
satisfactory, the complications and limitations associated
with PTA have caused interventional radiologists to search
for new approaches that can provide better patency for the
diseased vessel with smooth contours (4, 22, 23).
The placement of metallic vascular end prosthesis was
first used in interventional radiology more than 10 years
ago, and numerous reports have been published on this
technique’s success (9, 12, 13, 24). Since their first applica-
tions by Dotter, endovascular metallic stent placement has
been widely used for the treatment of aortoiliac occlusive
disease (7, 25, 26). Lesions that respond poorly to PTA,
such as complex calcified or eccentric stenoses, plaques
with ulceration or aneurysm formation, long segmental
stenoses with an irregular surface and also chronic
occlusions are the ones that are well indicated for stent
placement (23, 27, 28). 
In our study, the primary patency rates for all the limbs,
as determined by Kaplan-Meier analysis at 3, 5, 7, and 10
years, were 87%, 83%, 61% and 49%, respectively. The
patency rates of this study were relatively similar to those
reported by Schurmann, who reported a patency rate of
83% for 5 years with self-expandable stent placement in
110 patients (12). Vorwerk et al. reported a 4-year patency
rate of 78% and 82% for the primary and secondary
stenting procedures, respectively, in 100 patients (13, 28).
Cikrit and colleagues reported a 5-year patency rate of
63% in 38 limbs that were treated by Palmaz stent
placement, whereas Palmaz et al. initially reported a 92%
patency rate at 9 months (29). Primary 4-year patency
rates as high as 86% have been recently reported (7, 30).
The presumptive 7-year and 10-year patency rates in our
study showed a wide confidence interval (0.39 0.84 and
0.21 0.77, respectively), which wase not statistically
guaranteed for making comparison with the data of the
previous studies. De Vries and Hunink reported that the 5
year patency rates for the patients treated with aortoiliac
bypass surgery were 91% for the patients with claudica-
tion and 87.5% for the patients with ischemia (31). As
with our series and Schurmann’s series, the 5-year patency
rate of iliac artery stent placement was comparable to that
of surgical bypass grafting. 
Many series have studies various demographic and
clinical factors for determining their relationship with
primary stent patency. However, it is hard to conclude that
any of those factors have a constant and proven positive
relation with stent patency. The results of the aforemen-
tioned studies are affected by individual study design and
the statistical analysis. In our study, the lesions at the EIA
or the lesions that involved both the CIA and the EIA
showed poorer primary patency than did the lesions in the
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and it is more likely to have diffuse disease when
compared with the CIA. Although several multivariate
studies have failed to show the effect of the anatomic
location of a lesion on stent patency (32), lesions at the
external iliac artery are generally known as a poor predic-
tive factor for primary stent patency (33, 34). Johnston has
reported that the predicted 3-year success rate was 73%
for the patients with good run off and 30% for those
patients with poor runoff in 58 PTAs of both the common
iliac artery and the external iliac artery (33). In our series,
the total run off score showed a positive correlation with
primary stent patency on the Cox regression model.
Because most of the patients with a poor runoff vessel
underwent simultaneous or subsequent (less than one year)
bypass surgery (35%) in our series, this might have
contributed to the relatively better 5-year patency rate
than was seen in other reports. Stent diameter also showed
a positive correlation with primary stent patency on the
Cox regression model. In this study, it is unique that the
stents having the same or larger diameter than 10 mm
showed a 9.1% higher occlusion hazard rate than did the
stents having a diameter below 10 mm. It is possible that a
stent more than 10 mm in diameter is a burden for the
Asian population when considering their relatively smaller
vessel size. 
Our data indicate that none of the clinical risk factors,
including age, diabetes, hypertension and smoking, showed
a statistically significant influence on stent patency. We
defined a smoking history as a current smoker or as a
person who had abstained from smoking for 10 years or
less prior to their stenting procedure. All the patients
denied smoking after stenting, so we could not estimate the
result of the relationship between current smoking and
stenting. However, some of the patients with a smoking
history probably continued to smoke. 
In a study by Murphy and others that concentrated on
disease distribution, they concluded that the patency rates
for stenosis and occlusions were similar (35, 36);
moreover, diffuse disease produced the worst results, and
this conclusion was also reached by Dyet et al. (37). Long
and his colleague’s also reported good primary and
secondary patency rates for occlusions (38), as did Blum
(39). Although these variables were previously found to be
significant in an angioplasty series (6, 33, 40) and also in a
stenting series (41), our study showed that the lesion shape
and distribution such as diffuse disease, obstruction, and
the SCVIR classification did not affect the long-term
outcome of stenting.
In a series involving iliac angioplasty alone, Johnston et
al. have found a lower patency rate for women on a
subanalysis of the external iliac stenosis (6, 33). The
women’s smaller vessel size has been suggested to be a
possible reason for the decreased patency rates in women.
However, gender was not analyzed in our study because
the study population contained only 0.03% female
patients. The number of stents used in one limb and also
the stent type were not found to affect patency in our
present study.
Intra-arterial pressure measurements can provide defini-
tive information on the significance of a lesion. A
commonly accepted threshold of abnormality is a drop in
the systolic pressure of > 10 mm Hg (42). Indications for
selective stenting following angioplasty include a residual
systolic pressure gradient across the lesion of > 10 mm Hg
at rest or > 20 mm Hg after vasodilator challenge (43). We
obtained the same cutoff value, but the pressure gradients
of all the cases were not obtained; therefore, we could not
apply pressure gradient measurements to the multivariate
Cox model. However, the changes of the transstenotic
pressure gradient were statistically significant on paired t
testing (p = 0.00). 
Doppler US is used to follow iliac arterial stenting at
most institutions. Uberoi et al. have used Duplex US
during follow-up after stenting. They used the criteria of a
significant stenosis as either a visible lumen reduction of >
50% on power Doppler US or as more than a doubling of
the peak systolic velocities (> 2.5) (44). The angular course
of the iliac artery limits the use of the peak systolic
velocity. Moreover, any direct visualization of the vessel
patency on power Doppler US was limited due to pelvic
bowel gas, and the results could also be variable according
to the US machine. We also found that the monophasic
waveform of the CFA in the immediate phase was predic-
tive of stent stenosis. 
The limitations of our study were an insufficient number
of patients in the subgroup analysis such as for the pressure
gradient data, the ABI follow up data and the Doppler
ultrasonography data. Not all the patients had full data in
these categories and the application of the statistical
analysis was limited. Further, this study was conducted in a
retrospective fashion. From a statistical view point, includ-
ing too many independent variables in the multivariate
analysis can led to diminishing the testing power of the
Cox regression analysis. In addition, not all the patients
had objective imaging follow up results and some of the
follow up data was based on clinical/noninvasive examina-
tions for determining the patency of the stents.
Determination of patency without using a definitive
imaging modality always has pitfalls because the sympto-
matic aggravation does not always reflect stent obstruction
itself. Peripheral disease progression can also be present
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hand, symptomatic well being does not necessarily
represent good stent patency. The relative decrease in
daily activity that is due to the aging process or to other
physical condition can make the patient less sensitive to
any symptomatic aggravation. The degree of collateral
vessel development is another variable for symptom
aggravation with or without it compromising the stent
patency. 
In conclusion, our study indicates that a relatively high
level of long-term primary patency can be achieved for at
least five years by performing iliac arterial stenting.
However, the presumable 10-year patency was found to
be worse than that of bypass surgery. Additionally, lesions
involving the EIA or both the EIA and the CIA were poor
prognostic factors for the primary stent patency. A poor
run off score also diminished the primary stent patency. A
stent larger than 10 mm in diameter is probably not
recommendable for the Asian population because their
actual arterial diameter is somewhat small. As isolated
variables, none of the demographic and clinical factor had
an influence on the outcome of stent patency. Further long
term study with a full backdrop of imaging data will be
needed to determine the variable data on long term
patency rates. 
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